Incidence of hypoglycaemia in patients with type-2 diabetes taking multiple glucose lowering therapies during Ramadan: the PROFAST Ramadan Study
Objective To assess the incidence of hypoglycemia in people with type-2 diabetes mellitus (T2DM) on three or more anti-diabetic medications during Ramadan. Study design methods We have studied people with T2DM on three or more glucose-lowering drugs during Ramadan of H1438 (May–June 2017). The dose...
Gespeichert in:
| Veröffentlicht in: | Journal of diabetes and metabolic disorders 2018-12, Vol.17 (2), p.309-314 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 314 |
|---|---|
| container_issue | 2 |
| container_start_page | 309 |
| container_title | Journal of diabetes and metabolic disorders |
| container_volume | 17 |
| creator | Elhadd, Tarik Dabbous, Zeinab Bashir, Mohammed Elzouki, Abdulnasir Ghadban, Wissam Baagar, Khaled Benjamin, Silas Hassanien, Mohamed Saeed, Abazar A. M. Dukhan, Khaled Malik, Rayaz A. Abou-Samra, Abdul-Badie |
| description | Objective
To assess the incidence of hypoglycemia in people with type-2 diabetes mellitus (T2DM) on three or more anti-diabetic medications during Ramadan.
Study design methods
We have studied people with T2DM on three or more glucose-lowering drugs during Ramadan of H1438 (May–June 2017). The dose of each drug was adjusted according to a pre-specified protocol. The incidence of symptomatic or blood glucose confirmed hypoglycemia was recorded during the study.
Results
We enrolled 228 people with T2DM; 181 completed the study, and data on hypoglycaemia was available in 172 subjects. There were 115 males and 66 females, (mean age ± SD) 53.6 ± 9.7 years, diabetes duration 10 ± 6 yrs. The incidence of hypoglycaemia was 16.3% (28/172). Univariable logistic regression analysis showed that the risk of hypoglycaemia was increased in Arab subjects compared to Qatari; in those with longer duration of diabetes; and in those on four or more anti-diabetic medications compared to those on three anti-diabetic medications.
Conclusion
Despite the tailored advice, there is a high incidence of hypoglycemia in people with T2DM taking multiple glucose lowering therapies whilst fasting during Ramadan. Guidelines should address the increased complexity in anti-diabetic medications in patients who fast during Ramadan. Healthcare providers should individualize the modifications in anti-diabetic medications during Ramadan. |
| doi_str_mv | 10.1007/s40200-018-0374-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6405393</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A568040136</galeid><sourcerecordid>A568040136</sourcerecordid><originalsourceid>FETCH-LOGICAL-c568t-81dd53aa28107d1c737f19044a80a741a264b389544870d380bd645738db52eb3</originalsourceid><addsrcrecordid>eNp1kstu1TAQhiMEolXpA7BBlpBQNym-xXFYIB1VFCpVKmrL2nJs58TFsUPsUJ234JFxOL2cIogXsWa--e0Z_0XxGsFjBGH9PlKIISwh4iUkNS3xs2If4wqVrOLo-c5-rziM8Qbmr645R-xlsUdggzhnbL_4deaV1cYrA0IH-s0Y1m6jpBmsBNaDUSZrfIrg1qYepM1oSgy0la1JJoIkv1u_BsPskh2dAWs3qxANcOHWTEsm9WaSo82onv8ELuUgtfQflgz4enlxurq6vg-CqzTrzaviRSddNId3_4Pi2-mn65Mv5fnF57OT1XmpKsZTyZHWFZEScwRrjVRN6g41kFLJoawpkpjRlvCmopTXUBMOW81oVROu2wqblhwUH7e649wORqvc5SSdGCc7yGkjgrTiacbbXqzDT8EorEhDssDRncAUfswmJjHYqIxz0pswR4FRk4fMGG0y-vYv9CbMk8_tZYrnW5OqYo_UWjojrO9CPlctomKVe4YUIrJQx_-g8tL5zVTwprM5_qTg3U5Bb6RLfQxuTjb4-BREW1BNIcbJdA_DQFAslhNby4lsObFYTuBc82Z3ig8V9wbLAN4CcVwMYKbH1v-v-hstGd-i</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2189043556</pqid></control><display><type>article</type><title>Incidence of hypoglycaemia in patients with type-2 diabetes taking multiple glucose lowering therapies during Ramadan: the PROFAST Ramadan Study</title><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Elhadd, Tarik ; Dabbous, Zeinab ; Bashir, Mohammed ; Elzouki, Abdulnasir ; Ghadban, Wissam ; Baagar, Khaled ; Benjamin, Silas ; Hassanien, Mohamed ; Saeed, Abazar A. M. ; Dukhan, Khaled ; Malik, Rayaz A. ; Abou-Samra, Abdul-Badie</creator><creatorcontrib>Elhadd, Tarik ; Dabbous, Zeinab ; Bashir, Mohammed ; Elzouki, Abdulnasir ; Ghadban, Wissam ; Baagar, Khaled ; Benjamin, Silas ; Hassanien, Mohamed ; Saeed, Abazar A. M. ; Dukhan, Khaled ; Malik, Rayaz A. ; Abou-Samra, Abdul-Badie ; PROFAST Study Group ; for the PROFAST Study Group</creatorcontrib><description>Objective
To assess the incidence of hypoglycemia in people with type-2 diabetes mellitus (T2DM) on three or more anti-diabetic medications during Ramadan.
Study design methods
We have studied people with T2DM on three or more glucose-lowering drugs during Ramadan of H1438 (May–June 2017). The dose of each drug was adjusted according to a pre-specified protocol. The incidence of symptomatic or blood glucose confirmed hypoglycemia was recorded during the study.
Results
We enrolled 228 people with T2DM; 181 completed the study, and data on hypoglycaemia was available in 172 subjects. There were 115 males and 66 females, (mean age ± SD) 53.6 ± 9.7 years, diabetes duration 10 ± 6 yrs. The incidence of hypoglycaemia was 16.3% (28/172). Univariable logistic regression analysis showed that the risk of hypoglycaemia was increased in Arab subjects compared to Qatari; in those with longer duration of diabetes; and in those on four or more anti-diabetic medications compared to those on three anti-diabetic medications.
Conclusion
Despite the tailored advice, there is a high incidence of hypoglycemia in people with T2DM taking multiple glucose lowering therapies whilst fasting during Ramadan. Guidelines should address the increased complexity in anti-diabetic medications in patients who fast during Ramadan. Healthcare providers should individualize the modifications in anti-diabetic medications during Ramadan.</description><identifier>ISSN: 2251-6581</identifier><identifier>EISSN: 2251-6581</identifier><identifier>DOI: 10.1007/s40200-018-0374-2</identifier><identifier>PMID: 30918866</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Care and treatment ; Complications and side effects ; Diabetes ; Diabetics ; Endocrinology ; Glucose ; Health aspects ; Hypoglycemia ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Ramadan ; Religious aspects ; Research Article ; Risk factors ; Sawm (Fasting) ; Type 2 diabetes</subject><ispartof>Journal of diabetes and metabolic disorders, 2018-12, Vol.17 (2), p.309-314</ispartof><rights>Springer Nature Switzerland AG 2018</rights><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c568t-81dd53aa28107d1c737f19044a80a741a264b389544870d380bd645738db52eb3</citedby><cites>FETCH-LOGICAL-c568t-81dd53aa28107d1c737f19044a80a741a264b389544870d380bd645738db52eb3</cites><orcidid>0000-0003-3096-2641</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405393/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405393/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,41493,42562,51324,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30918866$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elhadd, Tarik</creatorcontrib><creatorcontrib>Dabbous, Zeinab</creatorcontrib><creatorcontrib>Bashir, Mohammed</creatorcontrib><creatorcontrib>Elzouki, Abdulnasir</creatorcontrib><creatorcontrib>Ghadban, Wissam</creatorcontrib><creatorcontrib>Baagar, Khaled</creatorcontrib><creatorcontrib>Benjamin, Silas</creatorcontrib><creatorcontrib>Hassanien, Mohamed</creatorcontrib><creatorcontrib>Saeed, Abazar A. M.</creatorcontrib><creatorcontrib>Dukhan, Khaled</creatorcontrib><creatorcontrib>Malik, Rayaz A.</creatorcontrib><creatorcontrib>Abou-Samra, Abdul-Badie</creatorcontrib><creatorcontrib>PROFAST Study Group</creatorcontrib><creatorcontrib>for the PROFAST Study Group</creatorcontrib><title>Incidence of hypoglycaemia in patients with type-2 diabetes taking multiple glucose lowering therapies during Ramadan: the PROFAST Ramadan Study</title><title>Journal of diabetes and metabolic disorders</title><addtitle>J Diabetes Metab Disord</addtitle><addtitle>J Diabetes Metab Disord</addtitle><description>Objective
To assess the incidence of hypoglycemia in people with type-2 diabetes mellitus (T2DM) on three or more anti-diabetic medications during Ramadan.
Study design methods
We have studied people with T2DM on three or more glucose-lowering drugs during Ramadan of H1438 (May–June 2017). The dose of each drug was adjusted according to a pre-specified protocol. The incidence of symptomatic or blood glucose confirmed hypoglycemia was recorded during the study.
Results
We enrolled 228 people with T2DM; 181 completed the study, and data on hypoglycaemia was available in 172 subjects. There were 115 males and 66 females, (mean age ± SD) 53.6 ± 9.7 years, diabetes duration 10 ± 6 yrs. The incidence of hypoglycaemia was 16.3% (28/172). Univariable logistic regression analysis showed that the risk of hypoglycaemia was increased in Arab subjects compared to Qatari; in those with longer duration of diabetes; and in those on four or more anti-diabetic medications compared to those on three anti-diabetic medications.
Conclusion
Despite the tailored advice, there is a high incidence of hypoglycemia in people with T2DM taking multiple glucose lowering therapies whilst fasting during Ramadan. Guidelines should address the increased complexity in anti-diabetic medications in patients who fast during Ramadan. Healthcare providers should individualize the modifications in anti-diabetic medications during Ramadan.</description><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Diabetes</subject><subject>Diabetics</subject><subject>Endocrinology</subject><subject>Glucose</subject><subject>Health aspects</subject><subject>Hypoglycemia</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Ramadan</subject><subject>Religious aspects</subject><subject>Research Article</subject><subject>Risk factors</subject><subject>Sawm (Fasting)</subject><subject>Type 2 diabetes</subject><issn>2251-6581</issn><issn>2251-6581</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kstu1TAQhiMEolXpA7BBlpBQNym-xXFYIB1VFCpVKmrL2nJs58TFsUPsUJ234JFxOL2cIogXsWa--e0Z_0XxGsFjBGH9PlKIISwh4iUkNS3xs2If4wqVrOLo-c5-rziM8Qbmr645R-xlsUdggzhnbL_4deaV1cYrA0IH-s0Y1m6jpBmsBNaDUSZrfIrg1qYepM1oSgy0la1JJoIkv1u_BsPskh2dAWs3qxANcOHWTEsm9WaSo82onv8ELuUgtfQflgz4enlxurq6vg-CqzTrzaviRSddNId3_4Pi2-mn65Mv5fnF57OT1XmpKsZTyZHWFZEScwRrjVRN6g41kFLJoawpkpjRlvCmopTXUBMOW81oVROu2wqblhwUH7e649wORqvc5SSdGCc7yGkjgrTiacbbXqzDT8EorEhDssDRncAUfswmJjHYqIxz0pswR4FRk4fMGG0y-vYv9CbMk8_tZYrnW5OqYo_UWjojrO9CPlctomKVe4YUIrJQx_-g8tL5zVTwprM5_qTg3U5Bb6RLfQxuTjb4-BREW1BNIcbJdA_DQFAslhNby4lsObFYTuBc82Z3ig8V9wbLAN4CcVwMYKbH1v-v-hstGd-i</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Elhadd, Tarik</creator><creator>Dabbous, Zeinab</creator><creator>Bashir, Mohammed</creator><creator>Elzouki, Abdulnasir</creator><creator>Ghadban, Wissam</creator><creator>Baagar, Khaled</creator><creator>Benjamin, Silas</creator><creator>Hassanien, Mohamed</creator><creator>Saeed, Abazar A. M.</creator><creator>Dukhan, Khaled</creator><creator>Malik, Rayaz A.</creator><creator>Abou-Samra, Abdul-Badie</creator><general>Springer International Publishing</general><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3096-2641</orcidid></search><sort><creationdate>20181201</creationdate><title>Incidence of hypoglycaemia in patients with type-2 diabetes taking multiple glucose lowering therapies during Ramadan: the PROFAST Ramadan Study</title><author>Elhadd, Tarik ; Dabbous, Zeinab ; Bashir, Mohammed ; Elzouki, Abdulnasir ; Ghadban, Wissam ; Baagar, Khaled ; Benjamin, Silas ; Hassanien, Mohamed ; Saeed, Abazar A. M. ; Dukhan, Khaled ; Malik, Rayaz A. ; Abou-Samra, Abdul-Badie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c568t-81dd53aa28107d1c737f19044a80a741a264b389544870d380bd645738db52eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Diabetes</topic><topic>Diabetics</topic><topic>Endocrinology</topic><topic>Glucose</topic><topic>Health aspects</topic><topic>Hypoglycemia</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Ramadan</topic><topic>Religious aspects</topic><topic>Research Article</topic><topic>Risk factors</topic><topic>Sawm (Fasting)</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elhadd, Tarik</creatorcontrib><creatorcontrib>Dabbous, Zeinab</creatorcontrib><creatorcontrib>Bashir, Mohammed</creatorcontrib><creatorcontrib>Elzouki, Abdulnasir</creatorcontrib><creatorcontrib>Ghadban, Wissam</creatorcontrib><creatorcontrib>Baagar, Khaled</creatorcontrib><creatorcontrib>Benjamin, Silas</creatorcontrib><creatorcontrib>Hassanien, Mohamed</creatorcontrib><creatorcontrib>Saeed, Abazar A. M.</creatorcontrib><creatorcontrib>Dukhan, Khaled</creatorcontrib><creatorcontrib>Malik, Rayaz A.</creatorcontrib><creatorcontrib>Abou-Samra, Abdul-Badie</creatorcontrib><creatorcontrib>PROFAST Study Group</creatorcontrib><creatorcontrib>for the PROFAST Study Group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of diabetes and metabolic disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elhadd, Tarik</au><au>Dabbous, Zeinab</au><au>Bashir, Mohammed</au><au>Elzouki, Abdulnasir</au><au>Ghadban, Wissam</au><au>Baagar, Khaled</au><au>Benjamin, Silas</au><au>Hassanien, Mohamed</au><au>Saeed, Abazar A. M.</au><au>Dukhan, Khaled</au><au>Malik, Rayaz A.</au><au>Abou-Samra, Abdul-Badie</au><aucorp>PROFAST Study Group</aucorp><aucorp>for the PROFAST Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence of hypoglycaemia in patients with type-2 diabetes taking multiple glucose lowering therapies during Ramadan: the PROFAST Ramadan Study</atitle><jtitle>Journal of diabetes and metabolic disorders</jtitle><stitle>J Diabetes Metab Disord</stitle><addtitle>J Diabetes Metab Disord</addtitle><date>2018-12-01</date><risdate>2018</risdate><volume>17</volume><issue>2</issue><spage>309</spage><epage>314</epage><pages>309-314</pages><issn>2251-6581</issn><eissn>2251-6581</eissn><abstract>Objective
To assess the incidence of hypoglycemia in people with type-2 diabetes mellitus (T2DM) on three or more anti-diabetic medications during Ramadan.
Study design methods
We have studied people with T2DM on three or more glucose-lowering drugs during Ramadan of H1438 (May–June 2017). The dose of each drug was adjusted according to a pre-specified protocol. The incidence of symptomatic or blood glucose confirmed hypoglycemia was recorded during the study.
Results
We enrolled 228 people with T2DM; 181 completed the study, and data on hypoglycaemia was available in 172 subjects. There were 115 males and 66 females, (mean age ± SD) 53.6 ± 9.7 years, diabetes duration 10 ± 6 yrs. The incidence of hypoglycaemia was 16.3% (28/172). Univariable logistic regression analysis showed that the risk of hypoglycaemia was increased in Arab subjects compared to Qatari; in those with longer duration of diabetes; and in those on four or more anti-diabetic medications compared to those on three anti-diabetic medications.
Conclusion
Despite the tailored advice, there is a high incidence of hypoglycemia in people with T2DM taking multiple glucose lowering therapies whilst fasting during Ramadan. Guidelines should address the increased complexity in anti-diabetic medications in patients who fast during Ramadan. Healthcare providers should individualize the modifications in anti-diabetic medications during Ramadan.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>30918866</pmid><doi>10.1007/s40200-018-0374-2</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-3096-2641</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2251-6581 |
| ispartof | Journal of diabetes and metabolic disorders, 2018-12, Vol.17 (2), p.309-314 |
| issn | 2251-6581 2251-6581 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6405393 |
| source | PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Care and treatment Complications and side effects Diabetes Diabetics Endocrinology Glucose Health aspects Hypoglycemia Medicine Medicine & Public Health Metabolic Diseases Ramadan Religious aspects Research Article Risk factors Sawm (Fasting) Type 2 diabetes |
| title | Incidence of hypoglycaemia in patients with type-2 diabetes taking multiple glucose lowering therapies during Ramadan: the PROFAST Ramadan Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T02%3A59%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20of%20hypoglycaemia%20in%20patients%20with%20type-2%20diabetes%20taking%20multiple%20glucose%20lowering%20therapies%20during%20Ramadan:%20the%20PROFAST%20Ramadan%20Study&rft.jtitle=Journal%20of%20diabetes%20and%20metabolic%20disorders&rft.au=Elhadd,%20Tarik&rft.aucorp=PROFAST%20Study%20Group&rft.date=2018-12-01&rft.volume=17&rft.issue=2&rft.spage=309&rft.epage=314&rft.pages=309-314&rft.issn=2251-6581&rft.eissn=2251-6581&rft_id=info:doi/10.1007/s40200-018-0374-2&rft_dat=%3Cgale_pubme%3EA568040136%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2189043556&rft_id=info:pmid/30918866&rft_galeid=A568040136&rfr_iscdi=true |